StemSpan™ Erythroid Expansion Supplement (100X)
Serum-free culture supplement for expansion of human erythroid cells
-
StemSpan™ Erythroid Expansion Supplement (100X) -
Label for StemSpan™ Erythroid Expansion Supplement (100X)
More Views
Overview
StemSpan™ Erythroid Expansion Supplement (100X) contains a combination of recombinant human cytokines (SCF, IL-3, and EPO) formulated to selectively promote the expansion and differentiation of erythroid progenitor cells from CD34+ cells isolated from human cord blood (CB) or bone marrow (BM) samples. StemSpan™ Erythroid Expansion Supplement is intended for use in combination with StemSpan™ SFEM, SFEM II, or any other media for culturing human hematopoietic cells. When added to serum-free medium, StemSpan™ Erythroid Expansion Supplement typically promotes the production of thousands of erythroid cells per input CD34+ cell in 14-day liquid cultures initiated with CD34+ human CB cells. See data section for more details.
Advantages:
• Formulated to produce large numbers of human erythroid cells in liquid cultures initiated with CD34+ CB or BM cells.
• Optimized for use with StemSpan™ media. When combined with StemSpan™ SFEM II in particular, supports up to 4-fold higher expansion of erythroid cells from human CD34+ CB cells than other serum-free media on the market.
• Supplied as a 100X concentrate. After thawing and mixing, the tube contents can be added directly to any hematopoietic cell expansion medium of choice.
• Optimized for use with StemSpan™ media. When combined with StemSpan™ SFEM II in particular, supports up to 4-fold higher expansion of erythroid cells from human CD34+ CB cells than other serum-free media on the market.
• Supplied as a 100X concentrate. After thawing and mixing, the tube contents can be added directly to any hematopoietic cell expansion medium of choice.
Contains:
• Recombinant human stem cell factor (SCF)
• Recombinant human interleukin 3 (IL-3)
• Recombinant human erythropoietin (EPO)
• Recombinant human interleukin 3 (IL-3)
• Recombinant human erythropoietin (EPO)
Subtype:
Supplements
Cell Type:
Hematopoietic Stem and Progenitor Cells; Erythroid Cells
Species:
Human
Application:
Cell Culture; Expansion; Differentiation
Brand:
StemSpan
Area of Interest:
Stem Cell Biology; Transplantation Research
Formulation:
Serum-Free
Related Products
-
Anti-Human CD71 (Transferrin Receptor) Antibody, Clone OKT9
Mouse monoclonal IgG1 antibody against human CD71 (transferrin receptor) -
Anti-Human CD235a (Glycophorin A) Antibody, Clone 2B7
Mouse monoclonal IgG1 antibody against human CD235a (glycophorin A) -
Serum-free medium for culture and expansion of hematopoietic cells
Scientific Resources
Product Documentation
Document Type
Product Name
Catalog #
Lot #
Language
Educational Materials
(10)
Product Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Research Area
Workflow Stages for
Workflow Stages
Data and Publications
Data
Figure 1. Production of Erythroblasts by Expansion and Lineage Specific Differentiation of CD34+ Human Cord Blood Cells Cultured in StemSpan™ SFEM Containing Erythroid Expansion Supplement
Flow cytometry dot plots showing expression of the HSPC marker CD34 and erythroid markers CD71 and glycophorin-A (GlyA) (A) before culture and (B,C) after 14 days of culture of enriched CD34+ CB cells in StemSpan™ SFEM containing Erythroid Expansion Supplement. The frequency of CD34+ cells declined from ~60% before culture to <0.1% after 14 days. In parallel, erythroid cells gradually accumulated from levels of <1% before culture to >90% by day 14. The bulk of cell population recovered from 14-day culture consisted of CD71+GlyA+ erythroblasts. More immature CD71+GlyA- progenitors and proerythroblasts, as well as more differentiated CD71-/low GlyA+ normoblasts were also present at low frequencies.
Table 1. Production of Erythroid Cells From CD34+ Human Cord Blood Cells Cultured in StemSpan™ SFEM Containing Erythroid Expansion Supplement
Numbers and percent of erythroid cells produced after 14 days of culture of enriched CD34+ cells from 14 different CB samples. *95% confidence limits; the range within which 95% of the results will typically fall.
Figure 2. Comparison of Erythroid Cell Expansion in Different StemSpan™ Media Containing Erythroid Expansion Supplement
(A) Average numbers and (B) frequencies of erythroid cells normalized relative to the values obtained in StemSpan™ SFEM (grey bars) after culturing purified CD34+ CB cells (n=6) for 14 days in StemSpan™ SFEM, SFEM II (gold bars) or ACF (orange bars) media containing Erythroid Expansion Supplement. Vertical lines indicate 95% confidence limits, the range within which 95% of results typically fall. Erythroid cell yields were significantly higher in SFEM II compared to ACF (p<0.01). Erythroid cell yields in SFEM II were also significantly higher than in SFEM for 5 of 6 CB samples tested (p<0.05).
Table 2. StemSpan™ Serum-Free Expansion Media and Erythroid Expansion Supplement
Publications
(3)
Stem cell research 2017
Peripheral blood derived induced pluripotent stem cells (iPSCs) from a female with familial hypertrophic cardiomyopathy.
Abstract
Abstract
Induced pluripotent stem cells (iPSCs) were generated from peripheral blood mononuclear cells (PBMCs) obtained from a 62-year-old female with familial hypertrophic cardiomyopathy (HCM). PBMCs were reprogrammed to a pluripotent state following transfection with non-integrative episomal vectors carrying reprogramming factors OCT4, SOX2, LIN28, KLF4 and L-MYC. iPSCs were shown to express pluripotency markers, possess trilineage differentiation potential, carry rare variants identified in DNA isolated directly from the patient's whole blood, have a normal karyotype and no longer carry episomal vectors for reprogramming. This line is a useful resource for identifying unknown genetic causes of HCM.
Stem cell research 2017
Generation of induced pluripotent stem cells (iPSCs) from a hypertrophic cardiomyopathy patient with the pathogenic variant p.Val698Ala in beta-myosin heavy chain (MYH7) gene.
Abstract
Abstract
Induced pluripotent stem cells (iPSCs) were generated from peripheral blood mononuclear cells (PBMCs) isolated from the whole blood of a 43-year-old male with hypertrophic cardiomyopathy (HCM) who carries the pathogenic variant p.Val698Ala in beta-myosin heavy chain (MYH7). Patient-derived PBMCs were reprogrammed using non-integrative episomal vectors containing reprogramming factors OCT4, SOX2, LIN28, KLF4 and L-MYC. iPSCs were shown to express pluripotent markers, have trilineage differentiation potential, carry the pathogenic MYH7 variant p.Val698Ala, have a normal karyotype and no longer carry the episomal reprogramming vector. This line is useful for studying the link between variants in MYH7 and the pathogenesis of HCM.
Science translational medicine 2016 OCT
Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells.
Abstract
Abstract
Genetic diseases of blood cells are prime candidates for treatment through ex vivo gene editing of CD34+ hematopoietic stem/progenitor cells (HSPCs), and a variety of technologies have been proposed to treat these disorders. Sickle cell disease (SCD) is a recessive genetic disorder caused by a single-nucleotide polymorphism in the $\beta$-globin gene (HBB). Sickle hemoglobin damages erythrocytes, causing vasoocclusion, severe pain, progressive organ damage, and premature death. We optimize design and delivery parameters of a ribonucleoprotein (RNP) complex comprising Cas9 protein and unmodified single guide RNA, together with a single-stranded DNA oligonucleotide donor (ssODN), to enable efficient replacement of the SCD mutation in human HSPCs. Corrected HSPCs from SCD patients produced less sickle hemoglobin RNA and protein and correspondingly increased wild-type hemoglobin when differentiated into erythroblasts. When engrafted into immunocompromised mice, ex vivo treated human HSPCs maintain SCD gene edits throughout 16 weeks at a level likely to have clinical benefit. These results demonstrate that an accessible approach combining Cas9 RNP with an ssODN can mediate efficient HSPC genome editing, enables investigator-led exploration of gene editing reagents in primary hematopoietic stem cells, and suggests a path toward the development of new gene editing treatments for SCD and other hematopoietic diseases.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.